Current role
Brian T. Crum
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Brian T. Crum
The proxy statement of Lexicon Pharmaceuticals, Inc. reports total compensation of $1,430,607 for Brian T. Crum in fiscal 2024, including a base salary of $473,503. Disclosed compensation is on record for 6 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Lexicon Pharmaceuticals, Inc. (LXRX)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Lexicon Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Michael Exton, Ph.D. CEO, Board Member
- Michael S. Exton CEO, Board Member
- Raymond Debbane Chairman
- Kristen L. Alexander CFO, Chief Accounting Officer
- Jeffrey L. Wade COO
- Christopher J. Sobecki Board Member
- Diane E. Sullivan Board Member
- Ivan H. Cheung Board Member
- Judith L. Swain Board Member
- Philippe J. Amouyal Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Lexicon Pharmaceuticals, Inc. (LXRX) | Senior Vice President and | $473,503 | $1,430,607 |
| 2023 | Lexicon Pharmaceuticals, Inc. (LXRX) | Senior Vice President and | $457,936 | $1,421,275 |
| 2022 | Lexicon Pharmaceuticals, Inc. (LXRX) | Senior Vice President and | $438,989 | $1,450,317 |
| 2021 | Lexicon Pharmaceuticals, Inc. (LXRX) | Senior Vice President and | $407,609 | $1,288,353 |
| 2020 | Lexicon Pharmaceuticals, Inc. (LXRX) | Senior Vice President and | $387,747 | $1,209,201 |
| 2019 | Lexicon Pharmaceuticals, Inc. (LXRX) | Vice President and | $369,287 | $932,885 |
Recent activity
No call appearances or filed executive changes recorded yet.